A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to find out how much of different medicines people can take together safely and effectively. They will test different combinations of these medicines and see which ones work best and are safe for patients.
This study wants to find out how much of different medicines people can take together safely and effectively. They will test different combinations of these medicines and see which ones work best and are safe for patients.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.